Page 6 - Pascal Touchon News Today

Nisa Investment Advisors LLC raised its stake in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 893.8% during the 3rd quarter, Holdings Channel.com reports. The fund owned 6,460 shares of the biotechnology company’s stock after purchasing an additional 5,810 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Atara Biotherapeutics were worth […]

Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023Cash Runway Extended into Q2 2024THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeut...

Following transfer of the EC marketing authorisation from Atara, Pierre Fabre will lead commercialisation of EBVALLO® in Europe.

Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the

Creative Planning grew its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) by 10.5% in the 3rd quarter, Holdings Channel reports. The firm owned 67,118 shares of the biotechnology company’s stock after purchasing an additional 6,390 shares during the period. Creative Planning’s holdings in Atara Biotherapeutics were worth $254,000 at the end of the […]

Oncology company exits from stealth with funding.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) has received a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average […]

Operator: Good afternoon, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics Third Quarter 2022 Financial Results Conference Call.

The EU approval of Atara Biotherapeutics' Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors.

Ebvallo™ is the first authorised allogeneic T-cell immunotherapy and has been approved for EU patients with relapsed or refractory EBV+ PTLD.